RT Journal Article SR Electronic T1 Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.01.12.23300401 DO 10.1101/2024.01.12.23300401 A1 Colijn, Mark A1 Vrijsen, Stephanie A1 Au, Ping Yee Billie A1 El Asrar, Rania Abu A1 Houdou, Marine A1 Van den haute, Chris A1 Sarna, Justyna A1 Montgomery, Greg A1 Vangheluwe, Peter YR 2024 UL http://medrxiv.org/content/early/2024/04/10/2024.01.12.23300401.abstract AB Biallelic (autosomal recessive) pathogenic variants in ATP13A2 cause a form of juvenile-onset parkinsonism, termed Kufor-Rakeb syndrome. In addition to motor symptoms, a variety of other neurological and psychiatric symptoms may occur in affected individuals, including supranuclear gaze palsy, spasticity, and cognitive decline. Although psychotic symptoms are often reported, response to antipsychotic therapy is not well described in previous case reports/series. As such, we describe treatment response in an individual with Kufor-Rakeb syndrome-associated psychosis. His disease was caused by a homozygous novel loss-of-function ATP13A2 variant (NM_022089.4, c.1970_1975del) that was characterized in this study. Our patient exhibited a good response to quetiapine monotherapy, which he has so far tolerated well. We also reviewed the literature and summarized all previous descriptions of antipsychotic treatment response. Although its use has infrequently been described in Kufor-Rakeb syndrome, quetiapine is commonly used in other degenerative parkinsonian disorders, given its lower propensity to cause extrapyramidal symptoms. As such, quetiapine should be considered in the treatment of Kufor-Rakeb syndrome-associated psychosis, when antipsychotic therapy is deemed necessary.Competing Interest StatementMC has no conflicts of interest directly relevant to this paper. MC is a co-investigator for a RCT in generalized anxiety disorder sponsored by Sunovion and Sumitomo, and a study physician for a RCT in major depressive disorder partially funded by Otsuka (part of CAN-BIND). He has not received any money from these companies for this work. PV is involved in a drug discovery program for ATP13A2 agonists for Parkinson disease.Funding StatementThe authors acknowledge the financial support of the Fonds Wetenschappelijk Onderzoek (FWO) Flanders (G094219N to P.V. and 1S88419N to S.V.). P.V., S.V., R.A.E.A., C.V.D.H. and M.H. are funded by the joint efforts of The Michael J. Fox Foundation for Parkinsons Research (MJFF) and the Aligning Science Across Parkinsons (ASAP) initiative. MJFF administers the grant ASAP-000458 on behalf of ASAP and itself.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The legal guardian of the patient has provided written informed consent for the publication of this report, and the patient himself has assented. The University of Calgary Conjoint Health Research Ethics Board (CHREB) has confirmed that this study does not require REB approval. That is, a waiver has been obtained retrospectively. This declaration has been added to the manuscript before the references.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll datasets generated or analyzed in this study can be found through the Zenodo depository. All experimental protocols can be found on protocols.io.